Source: Eur Respir Rev 2015; 25: 71-76
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Kempf Emmanuelle, Rousseau Benoît, Besse Benjamin, Paz-Ares Luis. KRAS oncogene in lung cancer: focus on molecularly driven clinical trials. Eur Respir Rev 2015; 25: 71-76

Member's Comments

No comment yet.

Related content which might interest you: Cost-effectiveness of KRAS, EGFR and ALK testing for decision making in advanced nonsmall cell lung carcinoma: the French IFCT-PREDICT.amm study Source: Eur Respir J, 51 (3) 1701467; 10.1183/13993003.01467-2017 Year: 2018 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 A variant in LKB1 gene can predicts the clinical outcomes of chemotherapy in patients with non-small cell lung cancer Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management Year: 2018 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype Source: Eur Respir J 2014; 43: 872-883 Year: 2014 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Survival prognosis and target therapy best response in adenocarcinoma lung cancer pts with mutation EGFR gene Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 Treatment landscape in oncogene driven advanced NSCLC Source: ERS Skills course: Multi-disciplinary care in thoracic oncology Year: 2019 EGFR, KRAS, HER2, BRAF and PI3KCA mutation status in metastatic cancer patients: Thoracic cytological specimens obtained in routine clinical practice Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations Source: Annual Congress 2006 - Lung cancer treatment Year: 2006 How novel targeted therapies have changed patient outcomes in ALK+ NSCLC Source: International Congress 2015 – Multidisciplinary approaches in the personalized care of the ALK + NSCLC patient Year: 2015 Detection of k-ras mutations in cytologic specimen of lung cancer patients as predictive factor of targeted therapy Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Therapeutic strategy for EGFR driven NSCLC Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Targeted therapies: detrimental treatment for nonsmall cell lung cancer without driver mutations Source: Eur Respir J 2015; 46: 19-21 Year: 2015